Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Stock Information for Cardiff Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiff Oncology Inc.

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Cardiff Oncology to Participate in Three Upcoming Investor Conferences 
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.